Our Investment Focus & Portfolio

Investments in Digital Health

Aignostics GmbH
Bodyport Inc
Brainomix, Ltd.
C-mo Medical Solutions
Dopavision GmbH
Optina Diagnostics
Perfood GmbH
Wellth
xCures

Aignostics GmbH

Aignostics

Aignostics, a spin-off from Charité – Universitätsmedizin Berlin and the Berlin Institute of Health, is pioneering computational pathology for pharmaceutical research and diagnostics. Its proprietary "Explainable AI" platform draws on research from Fraunhofer Society, Charité, and TU Berlin to overcome the typical "black-box" problem of AI in pathology. Aignostics' focus lies on developing bespoke AI models for clinical trials and CDx development.

Year of investment: 2020; BIVF Board Representative: Alexander Ehlgen
www.aignostics.com

Bodyport Inc

Bodyport Inc

Bodyport’s mission is to prevent and ultimately eliminate heart disease by empowering every person with high quality, actionable health information in their home.

Year of investment: 2019; BIVF Board Representative: Stefan Pflanz
www.bodyport.com

Brainomix, Ltd.

Brainomix, Ltd.

Brainomix, Ltd. focuses on imaging software for neurological and cerebrovascular diseases and developed a software tool (e-ASPECTS) for the automated analysis of CT scans to detect early ischemic changes in the brain of patients with clinical signs of stroke. Brainomix is a spin-out from the University of Oxford, UK.

Year of investment: 2018; BIVF Board Representative: Oliver Reuß
www.brainomix.com

C-mo Medical Solutions

C-mo Medical Solutions

C-mo Medical Solutions is a Digital Health start-up that develops solutions for the diagnosis and management of cough-incident medical conditions. The company’s mission is to unravel the clinical potential of cough assessment and solve the bold unmet medical need associated with the management of chronic cough.

Year of investment: 2022; BIVF Board Representative: Alexander Ehlgen
www.c-mo.solutions

Dopavision GmbH

Dopavision GmbH

Dopavision GmbH is developing a digital therapeutic for myopia which can be seamlessly and invisibly integrated while using a smartphone. The technology projects a light stimulus from a screen (e.g., a smartphone) into the eye to activate a neurotransmitter cascade which influences the correct development of the eyeball and thereby correct vision. Dopavision is headquartered in Berlin, Germany.

Year of investment: 2018; BIVF Board Representative: Oliver Reuß
www.dopavision.com

Optina Diagnostics

Optina Diagnostics

Optina Diagnostics specializes in the development of technology for early, non-invasive detection of disease via Retinal Deep PhenotypingTM. With an initial primary focus on the diagnosis of Alzheimer’s disease, Optina addresses the pressing need of millions of patients worldwide suffering from memory loss.

Year of investment: 2021; BIVF Board Representative: Adam Kundzewicz (until 2023)
www.optinadx.com

Perfood GmbH

Perfood GmbH

Perfood analyzes glycemic responses to meals, activity, symptoms, medication and gut microbiome on the basis of machine learning algorithms. This results in a pipeline of digital therapeutics based on personalized low-glycemic diet. At the same time, Perfood builds up a rich dataset for phenotyping.

Year of investment: 2020; BIVF Board Representative: Oliver Reuß
www.perfood.de

Wellth

Wellth

Wellth, Inc. applies behavioral economics through a mobile first, financial incentive focused behavior change platform to achieve better adherence, engagement, and health. The solution serves the most common chronic conditions. Wellth is headquartered in Brooklyn, NY.

Year of investment: 2018; BIVF Board Representative: Adam Kundzewicz (until 2023)
www.wellthapp.com

xCures, Inc.

xCures, Inc.

The xCures platform transforms complex unstructured medical data directly from the patient’s medical records into structured data suitable for analysis and machine learning. Our A.I. engine then actively cross-references this data against the vast digital library of oncology data to match patients with potential treatments and predict outcomes. This empowers patients and their oncologists to make more informed and effective treatment decisions.

Year of investment: 2021; BIVF Board Representative: Fei Shen
www.xcures.com